ReviewInternational urology and nephrology2013
Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.
Review in International urology and nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients.BioMed research international · 2014Trial
- Unraveling the Puzzle: Health Benefits of Probiotics-A Comprehensive Review.Journal of clinical medicine · 2024Review
- Effect of a Probiotic Mixture in Captive Cheetahs (Animals : an open access journal from MDPI · 2022Article
- Synbiotics Improved Stool Form via Changes in the Microbiota and Short-Chain Fatty Acids in Hemodialysis Patients.The Kobe journal of medical sciences · 2021Article
- The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders.Frontiers in endocrinology · 2018Review
- Mechanisms and therapeutic effectiveness of lactobacilli.Journal of clinical pathology · 2016Review
- The intestine and the kidneys: a bad marriage can be hazardous.Clinical kidney journal · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays kidney transplantation and dialysis are the only available therapies for end-stage renal disease management. They imply a considerable increase in plasma concentration of uremic wastes including creatinine, urea and uric acid. These invasive procedures impose high social costs that prevent many low-income countries from adequately treating the patients affected by renal insufficiency. For years, many studies on uremic waste removal through the gut lumen have been published with conflicting results. More recently, microencapsulation of probiotic bacteria has been performed by different research groups. This evidence has opened a new perspective on therapeutic modification of gut bacterial flora in the context of renal disease. This review gives an overview of the experimental and clinical use of probiotic formulations in the context of end-stage renal disease.
Indexed as
Identifiers
23584675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.